跳至主要内容
临床试验/EUCTR2006-002251-33-AT
EUCTR2006-002251-33-AT进行中(未招募)不适用

Hypoxia Imaging with the novel Radiopharmaceutical 18F Fluoroazomycin Arabinoside (FAZA)- Prognostic impact in Cervical Cancer . - 18F-FAZA

niversity of Vienna0 个研究点目标入组 25 人开始时间: 2006年10月30日最近更新:

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
25

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • First diagnosis of histologically proven cervical cancer FIGO stage IB2 to IVA.
  • Treatment intention for the purpose of achieving cure
  • Age < 80 years
  • No previous standard or radical hysterectomy
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Pregnancy, breast-feeding women, patients that are not able to lie motionless for one hour.
  • Palliative treatment, recurrent disease, neoadjuvant chemotherapy, other pre-existing malignancies, age > 80 years,

研究者

发起方
niversity of Vienna

相似试验